Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Alterations to the composition of the gut microbiota are associated with changes in the levels of serum metabolites during the development of cardiometabolic disease, before the onset of overt ischaemic heart disease.
A new study shows that atrial fibrillation causes functional remodelling of the left ventricle via impairment of excitation–contraction coupling of ventricular cardiomyocytes, which is mediated by reduced systolic Ca2+ release and increased levels of oxidative stress.
Cardiac pacing that restores heart rate variability in the form of respiratory sinus arrhythmia improves outcomes in a sheep model of heart failure with reduced ejection fraction.
A new study describes the efficacy of novel platelet-mimicking procoagulant nanoparticles in resisting clot lysis and improving clot stability, resulting in reduced bleeding in rodent models of thrombocytopenia and haemorrhage.
A new study shows that cardiovascular diseases remodel the bone marrow vasculature, inducing endothelial dysfunction, vascular leakage, fibrosis and angiogenesis and ultimately leading to overproduction of the inflammatory leukocytes implicated in these conditions.
Meta-analyses and cardiovascular outcome trials are laying the foundation for seasonal influenza vaccines to be a mainstay in the prevention of cardiovascular disease, rivalling established measures such as statin therapy. In this Clinical Outlook, we highlight current and future approaches for the use of influenza vaccination to reduce the risk of atherosclerotic cardiovascular disease and heart failure.